1. Amin M, Lehmann H, Mirmiran J. A double-blind, placebocontrolled dose-finding study with sertraline. Psychopharm Bull 1989;25:164–167.

2. Amsterdam JD, Berwish NJ. High dose tranylcypromine therapy for resistant depression. Pharmacopsychiatry 1989;22:21–25.

3. Amsterdam JD, Berwish NJ. Treatment of refractory depression with combination reserpine and tricyclic antidepressant therapy. J Clin Psychopharmacol 1987;7:238–242.

4. Ayd FJ, Zohar J. Psychostimulant (amphetamine or methylphenidate) therapy for chronic and treatment-resistant depression. In: Zohar J, Belmaker RH, eds. Treating resistant depression. New York: PMA Publishing; 1987:343–355.

5. Banki CM. Cerebrospinal fluid amine metabolites after combined amitriptylinetriiodothyronine treatment of depressed women. Eur J Clin Pharmacol 1977;11:311–315.

6. Beasley CM, Masica DN, Heiligensten JH, Wheadon DE, Zerbe RL. Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings. J Clin Psychopharm 1993;13:312–320.

7. Beasley CM, Sayler ME, Cunningham GE. Weiss AM, Masica DN. Fluoxetine in tricyclic refractory major depressive disorder. J Affect Disord 1990;20:193–200.

8. Bridges P. Psychosurgery for resistant depression. In: Zohar J, Belmaker RH, eds. Treating resistant depression. New York: PMA Publishing; 1987:397–411.

9. Bridges PK. ". . . and a small dose of an antidepressant might help." Br J Psychiatry 1983;142:626–628.

10. Brown RP, Sweeney J, Frances A, Kocsis JH, Loutsche E. Age as a predictor of treatment response in endogenous depression. J Clin Psychopharmacol 1983;3:176–178.

11. Brown WA, Harrison W. Are patients who are intolerant to one SSRI intolerant to another. Psychopharm Bull 1992;28:253–256.

12. Cain JW. Poor response to fluoxetine: underlying depression, serotonergic overstimulation, or a "therapeutic window." J Clin Psychiatry 1992;53:272–277.

13. Charney DS, Price LH, Heninger GR. Desipramine–yohimbine combination treatment of refractory depression. Arch Gen Psychiatry 1986;43:1155–1161.

14. Cole JO, Schatzberg AF, Sniffin C, Zolner J, Cole JP. Trazodone in treatment-resistant depression: An open study. J Clin Psychopharmacol 1981;1(Suppl.):49–54.

15. Cullen M, Mitchell P, Brodaty H, Boyce P, Parker G, Hickie I, Wilhelm K. Carbamazepine for treatment-resistant melancholia. J Clin Psychiatry 1991;52:472–476.

16. Davidson J, McLeod M, Law-Yone B, Linnoila M. A comparison of electroconvulsive therapy and combined phenelzine-amitriptyline in refractory depression. Arch Gen Psychiatry 1978;35:639–642.

17. Davidson J, Pelton S. Forms of atypical depression and their response to antidepressant drugs. Psychiatry Res 1986;17:87–95.

18. d'Elia G, Hanson L, Raotma H. L-Tryptophan and 5-hydroxytryptophan in the treatment of depression. A review. Acta Psychiatr Scand 1978;57:239–252.

19. DeCarolis V, Gilberti F, Roccatagliata G, et al. Imipramine and electroshock in the treatment of depression: A clinical statistical analysis of 437 cases. Dis Nerv Syst 1964;16:29–42.

20. Delgado PL, Price LH, Charney DS, Heninger GR. Efficacy of fluvoxamine in treatment-refractory depression. J Affect Disord 1988;15:55–60.

21. deMontigny C, Grunberg F, Mayer A, Deschenes JP. Lithium induces rapid relief of depression in tricyclic antidepressant drug non-responders. Br J Psychiatry 1981;138:252–256.

22. deMontigny C, Cournoyer G, Morissette R, Langlois R, Caille G. Lithium carbonate addition in tricyclic antidepressant-resistant unipolar depression. Arch Gen Psychiatry 1983;40:1327–1334.

23. Depression Guideline Panel. Clinical practice guideline. Depression in primary care: Vol. 2. Treatment of major depression. Rockville, MD: U.S. Dept. of Health and Human Services, Agency for Health Care Policy and Research; 1993:AHCPR publication no. 93-0551.

24. Devlin MJ, Walsh BT. Use of monoamine oxidase inhibitors in refractory depression. In: Tasman A, Goldfinger SM, Kaufman CA, eds. American psychiatric press review of psychiatry, Vol. 9. Washington, DC: American Psychiatric Press; 1990:74–90.

25. Dinan TG, Barry S. A comparison of electroconvulsive therapy with a combined lithium and tricyclic combination among depressed tricyclic nonresponders. Acta Psychiatr Scand 1989; 80:97–100.

26. Dunner DL, Dunbar GC. Optimal dose regimen for paroxetine. J Clin Psychiatry 1992;53:21–26.

27. Earle BV. Thyroid hormone and tricyclic antidepressants in resistant depressions. Am J Psychiatry 1970;126:143–145.

28. Faravelli C, Albanesi G, Sessarego A. Viqualine in resistant depression: A double-blind, placebo-controlled trial. Neuropsychobiology 1988;20:78–81.

29. Fawcett J, Kravitz HM. Treatment refractory depression. In: Schatzberg AE, ed. Common treatment problems in depression. Washington, DC: American Psychiatric Press; 1985.

30. Fawcett J, Kravitz HM, Zajecka JM, Schaff MR. CNS stimulant potentiation of monoamine oxidase inhibitors in treatmentrefractory depression. J Clin Psychopharmacology 1991;11: 127–132.

31. Feighner JP, Herbstein J, Damlouji N. Combined MAOI, TCA, and direct stimulant therapy of treatment-resistant depression. J Clin Psychiatry 1985;46:206–209.

32. Fontaine R, Ontiveros A, Elie R, Vézina M. Lithium carbonate augmentation of desipramine and fluoxetine in refractory depression. Biol Psychiatry 1991;29:946–948.

33. Frank E, Kupfer DJ. Axis II personality disorders and personality features in treatment-resistant and refractory depression. In: Roose SP, Glassman AH, eds. Treatment strategies for refractory depression. Washington, DC: American Psychiatric Press; 1990:205–221.

34. Gagiano CA, Muller PGM, Gourie J, LeRoux JF. The therapeutic efficacy of paroxetine: (a) an open study in patients with major depression not responding to antidepressants; (b) a double blind comparison with amitriptyline in depressed outpatients. Acta Psychiatr Scand 1993;80:130–131.

35. Garbutt JC, Mayo JP, Gillette GM, Little KY, Mason GA. Lithium potentiation of tricyclic antidepressants following lack of T3 potentiation. Am J Psychiatry 1986;143:1038–1039.

36. Georgotas A, Friedman E, McCarthy M, Mann J, Krakowski M, Siegel R, Ferris S. Resistant geriatric depressions and therapeutic response to monoamine oxidase inhibitors. Biol Psychiatry 1983; 18:195–205.

37. Gitlin MJ, Weiner H, Fairbanks L, Hershman JM, Friedfeld N. Failure to T3 to potentiate tricyclic antidepressant response. J Affect Dis 1987;13:267–272.

38. Goodnick PJ, Extein IL. Bupropion and fluoxetine in depressive subtypes. Ann Clin Psychiatry 1989;1:119–122.

39. Goodwin FK, Prange AJ, Post RM, Muscettola F, Lipton MA. Potentiation of antidepressant effects by L-triiodothyronine in tricyclic nonresponders. Am J Psychiatry 1982;139:34–38.

40. Guze BH, Baxter LR, Rego J. Refractory depression treated with high doses of a monoamine oxidase inhibitor. J Clin Psychiatry 1987;48:31–32.

41. Hamilton M. The effect of treatment on the melancholias (depressions). Br J Psychiatry 1982;40:223–230.

42. Hale AS, Procter AW, Bridges PK. Clomipramine, tryptophan and lithium in combination for resistant endogenous depression: seven case studies. Br J Psychiatry 1987;151:231–217.

43. Heninger GR, Charney DS, Sternberg DE. Lithium carbonate augmentation of antidepressant treatment. Arch Gen Psychiatry 1983;40:1335–1342.

44. Himmelhoch JM, Detre T, Kupfer DJ, Swartzburg M, Byck R. Treatment of previously intractable depressions with tranylcypromine and lithium. J Nerv Mental Dis 1972;155:216–220.

45. Joffe RT, Schuller DR. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. J Clin Psychiatry 1993;54:269–271.

46. Joffe RT, Singer W. A comparison of triiodothyronine and thyroxine in the potentiation of tricyclic antidepressants. Psychiatry Res 1990;32:241–251.

47. Joffe RT, Singer W, Levitt AJ, MacDonald C. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry 1993;50:387–393.

48. Jones JS, Stanley M. Serotonergic agents in the treatment of refractory depression. In: Roose SP, Glassman AH, eds. Treatment strategies for refractory depression. Washington, DC: American Psychiatric Press; 1990:143–167.

49. Joyce PR, Paykel ES. Predictors of drug response in depression. Arch Gen Psychiatry 1989;46:89–99.

50. Kahn D. Carbamazepine and other antiepileptic drugs in refractory depression. In: Roose SP, Glassman AH, eds. Treatment strategies for refractory depression. Washington, DC: American Psychiatric Press; 1990:75–107.

51. Kasper S, Ruhrmann S, van den Hoofdaker RH. Therapeutic sleep derivation in patients resistant to antidepressants. In: Maecher JP, Crocq MA, eds. The bioclinical interface. Proceedings from the IXth conference. Rouffach, France, Sept. 23–26 1992. Amsterdam: Elsevier (in press).

52. Katona CLE. Lithium augmentation in refractory depression. Psychiatr Devel 1988;2:153–171.

53. Kragh-Sorensen P, Hansen CE, Baastrup PC, Hvidberg FF. Self-inhibiting action of nortriptyline's antidepressive effect at high plasma levels. Psychopharmacologia 1976;45:305–312.

54. Kramlinger KG, Post RM. The addition of lithium to carbamazepine: antidepressant efficacy in treatment-resistant depression. Arch Gen Psychiatry 1989;46:794–800.

55. Lovett LM, Crimmins R, Shaw DM. Outcome in unipolar affective disorders after stereotactic tractotomy. Br J Psychiatry 1989;155: 547–550.

56. Magni G, Fisman M, Helmes E. Clinical correlates of ECTresistant depression in the elderly. J Clin Psychiatry 1988;49:405–407.

57. Mandel MR, Welch CA, Mieskie M, McCormick M. Prediction of response to ECT in tricyclic intolerant or tricyclic-resistant depressed patients. McLean Hosp J 1977;2:203–209.

58. McGrath PJ, Stewart JW, Nunes EV, Ocepek-Welikson K, Rabkin JG, Quitkin FM, Klein DF. A double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractory depression. Am J Psychiatry 1993;250:118–123.

59. Medical Research Council. Clinical trial of the treatment of depressive illness. Br Med J 1965;5439:881–886.

60. Miller IW, Bishop SB, Norman WH, Keitner GI. Cognitive/behavioural therapy and pharmacotherapy with chronic, drug-refractory depressed inpatients: a note of optimism. Behav Psychother 1985;13:320–327.

61. Nelson JC. The use of antipsychotic drugs in the treatment of depression. In: Zohar J, Belmaker RH, eds. Treating resistant depression. New York: PMA Publishing, 1987;131–146.

62. Nelson JC, Mazure CM. Lithium augmentation in psychotic depression refractory to combined drug treatment. Am J Psychiatry 1986;143:363–366.

63. Nelson JC, Mazure CM, Bowers MB, Jatlow P. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry 1991;48:303–307.

64. Nierenberg AA. Methodological problems in treatment resistant depression research. Psychopharm Bull 1990;26:461–464.

65. Nierenberg AA, Cole JO, Glass L. Possible-trazodone potentiation of fluoxetine: a case series. J Clin Psychiatry 1992;53:83–85.

66. Nierenberg AA, White K. What next? A review of pharmacologic strategies for treatment resistant depression. Psychopharm Bull 1990;26:429–460.

67. Nolen WA, Van De Putte JJ, Dijken WA, Kamp JS. L-5HTP in depression resistant to reuptake inhibitors: an open comparative study with tranylcypromine. Br J Psychiatry 1985;147:16–22.

68. Nolen WA, Van de Putte JJ, Dijken WA, Kamp JS, Blansjaar BA, Kramer HJ, Haffmans J. Treatment strategy in depression: I. Nontricyclic and selective reuptake inhibitors in resistant depression: A double-blind partial crossover study on the effects of oxaprotiline and fluvoxamine. Acta Psychiatr Scand 1988;78:668–675.

69. Nolen WA, Van De Putte JJ, Dijken WA, Kamp JS, Blansjaar BA, Kramer HJ, Haffmans J. Treatment strategy in depression: II. MAO inhibitors in depression resistant to cyclic antidepressants: Two controlled crossover studies with tranylcypromine versus L-5-hydroxytryptophan and nomifensine. Acta Psychiatr Scand 1988;78:676–683.

70. Nolen WA, Haffmans PMJ, Bouvy PF, Duivenvoorden HJ. Monoamine oxidase inhibitors in resistant major depression. A double-blind comparison of brofaromine and tranylcypromine in patients resistant to tricyclic antidepressants. J Affect Disord 1993;28:189–197.

71. Ogura C, Okuma T, Uchida Y, Imai S, Yogi H, Sumami Y. Combined thyroid (triiodothyronine)-tricyclic antidepressant treatment in depressive states. Folia Psychiatr Neurol Jpn 1974;28:179–186.

72. Oppenheim G, Zohar J, Shapiro B, Belmaker RH. The role of estrogen in treating resistant depression. In: Zohar J, Belmaker RH, eds. Treating resistant depression. New York: PMA Publishing; 1987:357–366.

73. Paul SM, Extein I, Calil HM, et al. Use of ECT with treatment resistant depressed patients at the National Institute of Mental Health. Am J Psychiatry 1981;138:486–489.

74. Peselow ED, Filippi AM, Goodnick P, Barouche F, Fieve RR. The short-and long-term efficacy of paroxetine HCl: B. Data from a double-blind crossover study and from a year-long trial vs. imipramine and placebo. Psychopharmacol Bull 1989;25:272–276.

75. Pope HW, Jonas JM, Hudson JI, Kafka MP. Toxic reactions to the combination of monoamine oxidase inhibitors and tryptophan. Am J Psychiatry 1985;142:491–492.

76. Post RM, Uhde TW. Carbamazepine as a treatment for refractory depressive illness and rapidly cycling manic-depressive illness. In: Zohar J, Belmaker RH, eds. Treating resistant depression. New York: PMA Publishing; 1987:175–235.

77. Poynton A, Bridges PK, Bartlett JR. Resistant bipolar affective disorder treated by stereotactic subcaudate tractotomy. Br J Psychiatry 1988;152:354–358.

78. Prange AJ. L-Triiodothyronine (T3): its place in the treatment of TCA-resistant depressed patients. In: Zohar J, Belmaker RH, eds. Treating resistant depression. New York: PMA Publishing; 1987:269–278.

79. Price LH. Lithium augmentation in tricyclic-resistant depression. In: Extein IL, ed. Treatment of tricyclic-resistant depression. Washington, DC: American Psychiatric Press; 1989:49–79.

80. Price LH, Charney DS, Delgado PL, Heninger GR. Fenfluramine augmentation in tricyclic-refractory depression. J Clin Psychopharmacol 1990;10:312–317.

81. Price LH, Conwell Y, Nelson JC. Lithium augmentation of combined neuroleptic-tricyclic treatment in delusional depression. Am J Psychiatry 1983;140:318–322.

82. Price LH, Charney DS, Heninger GR. Efficacy of lithium-tranylcypromine treatment in refractory depression. Am J Psychiatry 1985;142:619–623.

83. Price LH, Charney DS, Heninger GR. Reserpine augmentation of desipramine in refractory depression: clinical and neurobiological effects. Psychopharmacology [Berlin] 1987;92:431–437.

84. Prudic J, Sackheim HA, Devanand DP. Medication resistance and clinical response to electroconvulsive therapy. Psychiatry Res 1990;31:287–296.

85. Quitkin FM. The importance of dosing in prescribing antidepressants. Br J Psychiatry 1985;247:593–597.

86. Reimherr FW, Woods DR, Byerley B, Brainard J, Grosser BI. Characteristics of responders to fluoxetine. Psychopharm Bull 1984;20:70–72.

87. Robertson MM, Trimble MR. Major tranquilizers used as antidepressants. A review. J Affect Disorders 1982;4:173–193.

88. Ryan ND, Puig-Antich J, Rabinovich H, Fried J, Ambrosini P, Meyer V, Torres D, Dachille S, Mazzie D. MAOIs in adolescent major depression unresponsive to tricyclic antidepressants. J Am Acad Child Adolesc Psychiatry 1988;27(6):755–758.

89. Sackheim HA, Prudic J, Devanand DP. Treatment of medication resistant depression with electroconvulsive therapy. In: Tasman A, Goldfinger S, Kaufman CA, eds. American psychiatry press review of psychiatry, Vol. 9. Washington, DC: American Psychiatric Press; 1990:91–115.

90. Sackheim HA, Prudic J, Devanand DP, Decina P, Kerr B, Malitz S. The impact of medication resistance and continuation pharmacotherapy on relapse following response to electroconvulsive therapy in major depression. J Clin Psychopharmacol 1990;10:96–104.

91. Schatzberg AF, Cole JO, Cohen BM, Altesman RJ, Sniffin CM. Survey of depressed patients who have failed to respond to treatment. In: Davis JM, Maas J, eds. The affective disorders. Washington, DC: American Psychiatric Press; 1983:73–85.

92. Schmauss M, Laakmann G, Dieterle D. Nomifensine: A double-blind comparison of intravenous versus oral administration in therapy-resistant depressed patients. Pharmacopsychiatry 1985; 18:88–90.

93. Schopf J, Baumann P, Lemarchand T, Rey M. Treatment of endogenous depressions resistant to tricyclic antidepressants or related drugs by lithium addition: Results of a placebo-controlled double-blind study. Pharmacopsychiatry 1989;22:183–187.

94. Schweizer E, Rickels K, Amsterdam JD, Fox I, Puzzuoli G, Weise C. What constitutes an adequate antidepressant trial for fluoxetine? J Clin Psychiatry 1990;51:8–11.

95. Shapira B, Kindler S, Lerer B. Medication outcome in ECTresistant depression. Convulsive Therapy 1988;4:192–198.

96. Stein D, Avni J. Thyroid hormones in the treatment of affective disorders. Acta Psychiatr Scand 1988;77:623–636.

97. Stein G, Bernadt M. Lithium augmentation therapy in tricyclic-resistant depression. A controlled trial using lithium in low and normal doses. Br J Psychiatry 1993;162:634–640.

98. Steiner W, Fontaine R. Toxic reaction following the combined administration of fluoxetine and L-tryptophan: five case reports. Biol Psychiatry 1986;21:1067–1071.

99. Stern RA, Nevels CT, Shelhorse ME, Prohaska ML, Mason GA, Prange AJ. Antidepressant and memory effects of combined thyroid hormone treatment and electroconvulsive therapy: Preliminary findings. Biol Psychiatry 1991;30:623–627.

100. Stern WC, Harto-Truax N, Bauer N. Efficacy of bupropion in tricyclic-resistant or intolerant patients. J Clin Psychiatry 1983; 44:148–152.

101. Targum SD, Greenberg RD, Harmon RL, Kessler K, Salerian AJ, Fram DH. Thyroid hormone and the TRH stimulation in refractory depression. J Clin Psychiatry 1984;45:345–346.

102. Thase ME, Frank E, Mallinger AG, Hammer T, Kupfer DJ. Treatment of imipramine-resistant recurrent depression: III. Efficacy of monoamine oxidase inhibitors. J Clin Psychiatry 1992;53:5–11.

103. Thase ME, Howland RH. Refractory depression: relevance of psychosocial factors and therapies. Psychiatr Ann [in press].

104. Thase ME, Kupfer DJ. Characteristics of treatment-resistant depression. In: Zohar J, Belmaker RH, eds. Treating resistant depression. New York: PMA Publishing; 1987:23–45.

105. Thase ME, Kupfer DJ, Jarrett DB. Treatment of imipramine-resistant recurrent depression: I. An open clinical trial of adjunctive L-triiodothyronine. J Clin Psychiatry 1989;50:385–388.

106. Thase ME, Kupfer DJ, Frank E, Jarrett DB. Treatment of imipramine-resistant recurrent depression: II. An open clinical trial of lithium augmentation. J Clin Psychiatry 1989;50:413–417.

107. Thase ME, Frank E, Mallinger AG, Hammer T, Kupfer DJ. Treatment of imipramine-resistant recurrent depression: III. Efficacy of monoamine oxidase inhibitors. J Clin Psychiatry 1992;53:5–11.

108. Thase ME, Mallinger AG, McKnight D, Himmelhoch JM. Treatment of imipramine-resistant recurrent depression: IV. A double-blind, cross-over study of tranylcypromine in anergic bipolar depression. Am J Psychiatry 1992;149:195–198.

109. Thase ME, Rush AJ, Kasper S, Nemeroff C. Tricyclics and newer antidepressant medications: treatment options for treatment resistant depressions. Depression [in press].

110. Thase ME, Shipley JE. Tricyclic antidepressants. In: Last CG, Hersen M, eds. Handbook of anxiety disorders. New York: Pergamon Press; 1988:460–477.

111. Tsutsui S, Yamazaki Y, Namba T, Tsushima M. Combined therapy of T3 and antidepressants in depression. J Int Med Res 1979; 7:138–146.

112. van Marwijk HWJ, Bekker FM, Nolen WA, Jansen PAF, van Nieuwkerk, Hop WCJ. Lithium augmentation in geriatric depression. J Affect Disord 1990;20:217–223.

113. Walinder J, Carlsson A, Persson R. 5-HT reuptake inhibitors plus tryptophan in endogenous depression. Acta Psychiatr Scand 1981;290(Suppl):179–190.

114. Wehr TA, Rosenthal NE. Sleep deprivation, phototherapy, and other nonpharmacological treatments of affective illness. In: Extein IL, ed. Treatment of tricyclic-resistant depression. Washington, DC: American Psychiatric Press; 1989:153–167.

115. Weilburg JB, Rosenbaum JF, Biederman J, Sachs GS, Pollack MH, Kelly K. Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders: a preliminary report. J Clin Psychiatry 1989;50:447–449.

116. Wernicke JF, Dunlop SR, Dornseif BE, Zerbe RL. Fixed-dose fluoxetine therapy for depression. Psychopharm Bull 1987;23: 164–168.

117. White K, Wykoff W, Tynes LL, Schneider L, Zemansky M. Fluvoxamine in the treatment of tricyclic-resistant depression. Psychiatr J Univ Ottawa 1990;15:156–158.

118. Zohar J, Lerer B, Belmaker RH. Beta-2 adrenergic agonists for depression as a potential treatment. In: Zohar J, Belmaker RH, eds. Treating resistant depression. New York: PMA Publishing; 1987:375–380.

119. Zohar J, Moscovich D, Mester R. Addition of reserpine to tricyclic antidepressants in resistant depression. In: Zohar J, Belmaker RH, eds. Treating resistant depression. New York: PMA Publishing; 1987:367–374.